Innate Pharma to Showcase Cancer Immunotherapy Innovations at H.C. Wainwright and Wolfe Research Conferences

Innate Pharma will participate in two virtual healthcare conferences in June 2025 to showcase its innovative cancer immunotherapies. The company focuses on multi-specific NK Cell Engagers, ADCs, and mAbs for various cancer types, with collaborations with AstraZeneca and Sanofi. Innate Pharma's shares are traded on Euronext Paris and Nasdaq under the ticker IPHA, with a market capitalization of approximately $191.69 million.

Innate Pharma SA, a global biotechnology company specializing in cancer immunotherapies, will participate in two virtual healthcare conferences in June 2025 to showcase its innovative treatments. The company is focused on developing multi-specific NK Cell Engagers, Antibody Drug Conjugates (ADCs), and monoclonal antibodies (mAbs) for various cancer types. Innate Pharma has collaborations with AstraZeneca and Sanofi and is listed on Euronext Paris and Nasdaq under the ticker IPHA, with a market capitalization of approximately $191.69 million.

At the European Hematology Association (EHA) Congress 2025, Innate Pharma presented preclinical data for its novel Anket, IPH6501. IPH6501 is an investigational therapy targeting CD20 and is currently being explored in a Phase 1/2 study for relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) [1]. The treatment landscape for B-NHL is evolving, with novel approaches including T cell engagers, antibody-drug conjugates, and CAR-T cells. However, a significant medical need persists for patients resistant to or relapsed from these treatments.

Preclinical tests have shown that IPH6501 enhances natural killer cell proliferation and effectively kills tumor cells in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) samples. Its robust performance in rituximab-resistant tumor models, even alongside rituximab, suggests a potential synergy. Additionally, in combination with R-CHOP, the standard of care for untreated DLBCL and FL patients, IPH6501 demonstrated improved antitumor effects, suggesting its potential to enhance the current standard of care [2].

These encouraging findings pave the way for further exploration of combination therapies in B-NHL. Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma, commented that the encouraging activity observed in preclinical models with IPH6501, including in rituximab-resistant settings, suggests its potential to offer new treatment options for B-cell non-Hodgkin lymphoma. The enhanced antitumor activity in combination with R-CHOP could support further investigation in untreated patients.

Innate Pharma's portfolio includes several ANKET® drug candidates to address multiple tumor types, as well as IPH4502, a differentiated ADC in development in solid tumors. The company's anti-KIR3DL2 mAb lacutamab is developed in advanced forms of cutaneous T cell lymphomas and peripheral T cell lymphomas, and its anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

References:
[1] https://www.businesswire.com/news/home/20250612105785/en/Innate-Pharma-Highlights-Preclinical-Antitumor-Activity-of-IPH6501-in-Diffuse-Large-B-Cell-Lymphoma-and-Follicular-Lymphoma-at-the-2025-European-Hematology-Association-EHA-Congress
[2] https://www.gurufocus.com/news/2925663/innate-pharma-ipha-advances-innovative-treatment-for-bcell-lymphomas-ipha-stock-news